Biotech companies at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
34 biotech companies are at Antibody Engineering 2026 — 46 presentations on the program and 2 with a booth in the exhibit hall. Most represented: Xencor (4 on the program), Rondo Therapeutics (2 on the program), Genmab (2 on the program). 8 of them have their own page in this guide. As of Nov 10, 2026.
Topic
Top represented
Showing 1–15 of 34 organizations
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
Xencor Pasadena, CA | |
Develops engineered antibodies using its XmAb Fc and bispecific technologies, for cancer and autoimmune diseases. | Chair Sun Dec 13 1:00pm–1:15pm Talk Sun Dec 13 4:15pm–5:00pm Chair Mon Dec 14 8:00am–8:05am Talk Mon Dec 14 10:55am–11:30am Chair Wed Dec 16 8:10am–8:15am Talk Wed Dec 16 9:15am–9:45am XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life Redesigned antibody arms that pair only with their intended partner, used to build two-target antibodies that last longer in blood. Bispecifics & multispecifics |
RT Rondo Therapeutics Hayward, CA | |
Develops bispecific T cell engagers, including co-stimulatory CD28 bispecifics, for solid tumors. | Chair Sun Dec 13 9:00am–9:10am Session Co-Chair Welcome and Opening Remarks Short research talks by scientists within ten years of their graduate degree, plus career advice and time to meet peers. Chair Tue Dec 15 2:25pm–2:30pm Talk Tue Dec 15 2:30pm–3:00pm Combination of Signal 1 and Signal 2 T Cell Engagers for Treatment of Ovarian Cancer Pairing two antibodies that give T cells both of the signals they need, aiming at ovarian cancer that no longer responds to platinum drugs. Chair Wed Dec 16 8:10am–8:15am |
Genmab Copenhagen, Denmark | |
Danish antibody company with marketed cancer medicines, developing bispecific antibodies and antibody-drug conjugates. | Chair Tue Dec 15 2:25pm–2:30pm Talk Wed Dec 16 11:30am–12:00pm Enabling Polyclonal Antibody Production through Fc-engineering of Mutual Exclusive CH3 Interfaces Reshaping the region where two antibody halves join, so several different antibodies can be made together in one mixture without mismatching. |
Gyes Naarden, Netherlands | |
Dutch biotech building multispecific antibodies that act only on cells co-expressing target combinations, for cancer and immune diseases. | Chair Mon Dec 14 8:00am–8:05am Chair Wed Dec 16 2:10pm–2:15pm |
Develops multispecific antibody therapeutics and antibody–drug conjugates using its Azymetric bispecific and other protein engineering platforms. | Talk Sun Dec 13 1:45pm–2:15pm Engineering Conditional Co-stimulation: Key Considerations for Developing Next-Generation T Cell Engagers What to get right, from target choice to safety testing, when building T-cell-recruiting antibodies with a built-in second signal. Bispecifics & multispecifics Talk Wed Dec 16 8:45am–9:15am Engineering Trispecific T Cell Engagers (TriTCEs) For Optimal Activity and Developability Antibodies that bind three things at once to give T cells an extra activating signal inside solid tumors. Developability & CMC |
Immunology company developing antibody-based medicines for autoimmune diseases, with marketed FcRn-blocking therapy. | Talk Wed Dec 16 4:45pm–5:15pm A Novel Antibody Approach to Pan-subclass IgG Reduction An antibody that sweeps up and destroys every subtype of the main antibody class in blood, for diseases caused by self-attacking antibodies. Beyond oncology |
Biotech with no public profile yet; on this program it co-chairs the track on engineering antibodies for difficult targets. | Talk Sun Dec 13 11:00am–11:45am Chair Mon Dec 14 2:25pm–2:30pm |
Vaccinex Rochester, NY | |
Develops pepinemab, an antibody against SEMA4D, for Alzheimer's and Huntington's disease and cancer, and offers ActivMab discovery against membrane-protein targets. | Booth Exhibiting (no floor booth listed) Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Tue Dec 15 10:00am–10:20am Antibody Discovery for Complex Membrane Antigens How complex membrane proteins built into the membranes of two viruses serve as ready-made targets for finding antibodies in libraries or immunized animals. Antibody discoveryProtein engineering |
Adaxion Therapeutics San Diego, CA | |
Develops biologics with a deimmunization platform meant to stop patients making anti-drug antibodies against them. | Talk Sun Dec 13 11:00am–11:45am |
AB Amberstone Biosciences | |
Preclinical oncology company developing pH-gated, tumor-activated T-cell engagers on its T-MATE platform. | Talk Tue Dec 15 5:45pm–6:15pm Rewriting the Safety–Efficacy Balance: Engineering Conditionally Activated TCEs for Solid Tumors. T-cell-recruiting antibodies switched on by the slightly acidic conditions inside solid tumors and quiet in healthy tissue. |
AV Atlas Venture NewCo | |
Unnamed new company being built by the venture firm Atlas Venture, with its own antibody discovery and engineering scientists. | Chair Sun Dec 13 1:00pm–1:15pm |
BigHat Biosciences San Mateo, CA | |
Designs antibody therapeutics with machine learning and a high-throughput wet lab; runs its own pipeline and pharma partnerships. | Talk Tue Dec 15 5:15pm–5:45pm Machine Learning Guided Design of Avidity- and Logic-Gated T Cell Engagers Using machine learning to tune binding strength so T-cell-recruiting antibodies act on diseased cells and spare healthy ones. AI & computational design |
C Chennaibio San Carlos, CA | |
San Carlos biotech working on multiparatopic antibodies, which bind several sites on one target, the subject of its talk here. | Talk Tue Dec 15 8:45am–9:15am |
Commit Biologics Aarhus, Denmark | |
Aarhus University spin-out developing bispecific complement-engaging antibodies for cancer and autoimmune disease. | Keynote Mon Dec 14 9:15am–9:50am The Evolution of Antibody Therapies in Autoimmunity: From Toxic Immunosuppressant to Precision Modulator of Disease How antibody drugs for autoimmune disease moved from broadly damping the immune system to targeting single faulty pathways. Beyond oncology |
Divergence Labs New York, NY | |
Drug developer combining computational models and lab work to discover medicines, with ophthalmology programs in its pipeline. | Talk Mon Dec 14 3:00pm–3:30pm One-Shot Antibody Design with AI: Are We There Yet? An assessment of how much of computer-designed antibody discovery really works today, and what still does not. AI & computational design |
Find buyers from biotech companies
Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse Antibody Engineering 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction